Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24489412 | 0.94 | SELE (0.77) | SELE | |
| SCHEMBL21992391 | 0.91 | SELE (0.68) | SELE | |
| SCHEMBL21992394 | 0.91 | SELE (0.66) | SELE | |
| SCHEMBL24489336 | 0.91 | SELE (0.66) | SELE | |
| SCHEMBL21992395 | 0.89 | SELE (0.76) | SELE | |
| SCHEMBL21991839 | 0.89 | SELE (0.76) | SELE | |
| SCHEMBL24489363 | 0.87 | SELE (0.85) | SELE | |
| SCHEMBL26408558 | 0.86 | SELE (0.81) | SELE | |
| SCHEMBL21992404 | 0.86 | SELE (0.76) | SELE | |
| SCHEMBL17151665 | 0.86 | SELE (0.80) | SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175808-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-11197877-B2 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | GLYCOMIMETICS. INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200129536-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175808-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | SELE, SELPLG, SELP | SELE 1/4885 |
| US-11197877-B2 | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists | SELE, SELPLG, SELP | SELE 1/4885 |
| US-20200129536-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | SELE, SELPLG, SELP | SELE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.